ITGB5 promotes innate radiation resistance in pancreatic adenocarcinoma by promoting DNA damage repair and the MEK/ERK signaling pathway

Xin Wen, Si Chen, Xueting Chen, Hui Qiu, Wei Wang, Nie Zhang, Wanming Liu, Tingting Wang, Xin Ding and Longzhen Zhang

1Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, 2Cancer Institute of Xuzhou Medical University, Xuzhou, China, 3Department of Radiation Oncology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, China, 4Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou, China

Pancreatic adenocarcinoma (PAAD) is one of the most aggressive digestive system tumors in the world, with a low early diagnosis rate and a high mortality. Integrin beta 5 (ITGB5) is demonstrated to be a potent tumor promoter in several carcinomas. However, it is unknown whether ITGB5 participates in the occurrence and development of PAAD. In this study, we confirmed a high expression of ITGB5 in PAAD and its role in promoting invasiveness and transitivity in PAAD. Besides, the knockdown of ITGB5 increased cell sensitivity to radiation by promoting DNA damage repair and the MEK/ERK signaling pathway. Collectively, these results show that ITGB5 plays an essential role in pancreatic cancer growth and survival.

KEYWORDS
pancreatic adenocarcinoma (PAAD), ITGB5, radio-sensitivity, MEK/ERK signaling pathway, DNA damage repair

Introduction

Pancreatic adenocarcinoma (PAAD), also known as “the king of carcinoma”, is one of the most aggressive cancers. In recent decades, in the context of other cancer treatment outcomes significantly improved, it has remained a huge clinical challenge to manage in PAAD. Due to the lower early diagnosis and a lack of effective therapeutic options, the 5-year survival rate of PAAD is only 9% (1, 2). According to changing demographics and the annual average percentage change in incidence rate and death rate, by 2030, PAAD is projected to be the second leading cause of cancer-related death (3). It may be one
effective way to improve the current poor treatment status by finding PAAD surface molecules that can be targeted by therapeutics.

Integrins are a superfamily of heterodimeric somatic surface receptors and are composed of $\alpha$ (120–185 kD) and $\beta$ (90–110 kD) subunits. So far, at least 18 $\alpha$ subunits and 8 $\beta$ subunits have been found, resulting in 24 heterodimers (4). Multiple integrins have been demonstrated in tumor progression by regulating different biological functions, making them attractive and potential target molecules for tumor therapy (5–7). Integrin-ß5 (ITGB5) is a member of integrins and was proved to be associated with pathological processes in several tumors (6, 8, 9). However, the function of ITGB5 in PAAD is not clear.

On the one hand, radiotherapy (RT) is one effective antitumor technology for local control in advanced PAAD (10, 11). On the other hand, irradiation can induce DNA damage response, also known as DDR, which may protect cells from irradiation-induced DNA damage, ultimately showing radio-resistance (12). RT has limited application because of innate radiotherapy resistance in PAAD. Currently, gemcitabine and capecitabine were reported as radiosensitizers for PAAD, but the overt toxicity and side effects are usually intolerant. ITGB5 was reported to contribute to chemoresistance such as cisplatin in numerous malignancies (13, 14). However, whether ITGB5 expression can weaken or strengthen innate resistance to radiotherapy in PAAD is unknown.

Studies have reported that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathways took part in the regulation of cell proliferation by transferring signals from the cell membrane to the nucleus. In the MAPK/ERK pathway, ligand binding to the plasma membrane receptor tyrosine kinases results in small GTPase RAS activation, which is followed by a series of protein interactions and phosphorylation events such as RAF phosphorylation and MAPK kinase (MEK) activation. ERK is the only substrate of MEK and is phosphorylated by MEK directly (15, 16). ERK phosphorylation activates multiple substrates, which then regulate cell proliferation, apoptosis, metabolism, and immune response (17). The deregulation of the MEK/ERK pathway is common in cancer, such as ovarian cancer, melanoma, and PAAD (17, 18). Besides, MEK/ERK inhibitors are proved to increase the radiosensitivity of cancer cells (19). However, the relationship of ITGB5 and MEK/ERK pathway is unknown.

In our study, we first investigated the ITGB5 expression level in PAAD and abnormally elevated ITGB5 contributed to a poor survival outcome. Mechanisms shown in Figure 1 were examined and showed that ITGB5 promotes proliferation, invasion, and migration by activating the MEK/ERK pathway; besides, ITGB5 protected pancreatic cancer cells from radiation through activating the DNA injury repair pathway including DNA-PK as well as ATM.

**Materials and methods**

**Cell culture**

Human pancreatic cancer cell lines including BXPC3, PANC-1, and ASPC-1 as well as human normal pancreatic cells HPDE6-C7 were obtained from the Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy. PANC-1, ASPC-1, and HPDE6-C7 were cultured in DMEM (sigma, D5796) with 10% fetal bovine serum (FBS), and 1% penicillin, streptomycin, and BXPC3 were cultured in RPMI-1640 medium.
(sigma, R8758) with 10% FBS and 1% penicillin and streptomycin at 37°C, 5% CO2.

Transfection

We designed two small guide RNAs for knocking out ITGB5 by the CHOPCHOP web tool (20):

sgITGB5-1: 5′-CACCGCTTTCTCCTACACGGCACCG-3′
sgITGB5-2: 5′-CACCGCTGGCGAACCTGTAGCTGGA-3′

293T cells growing on a 6-cm dish were firstly transfected with 4 µg pCDH-ITGB5 or LentiCRISPR-ITGB5 or control vector (pCDH, LentiCRISPR V2), 3 µg PSPAX2, 1 µg PMD2G, and Lipofectamine 2000 for obtaining lentivirus expressing ITGB5. Forty-eight hours after transfection, the culture medium supernatant was centrifuged to remove cell debris at 1,000 rpm, 5 min for infection. PANC1 or BXPC3 cells seeded on a 6-cm dish with 60% cell density were infected by the above supernatant, and then stable ITGB5 knockout cell lines (ITGB5-KO) or ITGB5 overexpression cell lines (ITGB5-OE) with puromycin for 3 days were selected. Western blot analysis was used to evaluate the ITGB5 expression efficiency.

Antibodies

ITGB5 was obtained from Abcam (ab184312, Abcam) and Novus Biologicals (NBP1-88117, Novus Biologicals) for Western blot and immunohistochemistry (IHC) studies, respectively. MEK1/2 (9154T) and γ-H2AX (9718S) were from Cell Signaling Technology (CST). Ki67 (11680S), ERK, and pERK (A11116) were from ABclonal. KU70 (10723-1-AP), KU80 (10724-1-AP), RAD51 (10725-1-AP), CHEK2 (13954-1-AP), Phospho-CHEK2 (Thr68) (29012-1-AP), PAX6 (12323-1-AP), STAT1 (10144-2-AP), GAPDH (10494-1-AP), and β-actin (23660-1-AP) were from Proteintech. DNA-PKcs (BS1092) was from Bioworld. HRP-Goat Anti-Rabbit IgG (VA001) and HRP-Goat Anti-Mouse IgG (VA002) were obtained from Vicmed.

Immunohistochemistry

IHC was conducted as previously described (21). Simply, we used the PV-9000 two-step immunohistochemistry kit and DAB color reagent (ZSBIO) to detect antigens in human PAAD tissue microarrays (TMA) (HPanA 1505u01, Shanghai Outdo Biotech, China) and mouse tissue samples according to the manufacturer’s instruction.

Cell proliferation and colony formation assay

CCK-8 and colony formation assays were used to evaluate the influence of ITGB5 on the tumor cells’ growth rate. ITGB5-KO, ITGB5-OE, and control BXPC3 and PANC-1 cells were seeded into 96-well plates (1,000 cells per well). The changes in cell number were detected with a CCK-8 assay kit continuously for 4 days. The absorbance at 450 nm (OD450) of cells was measured by a microplate reader. Furthermore, cell proliferation ability was further detected by colony formation assays. The equal number of cancer cells was seeded in six-well plates with appropriate density and cultured for 10–14 days at 37°C, 5% CO2. The medium was replaced every 3 days. In radiation sensitization assays, cancer cells with appropriate cell intensity seeded in six-well plates were one-off irradiated with 0, 2, 4, 6, and 8 Gy, respectively, at a dose rate of 300 cGy/min. All cells were irradiated with 6-MeV X-ray, and the source-surface distance was 100 cm. Besides, the surface of plates was covered with a 1-cm-thick tissue equivalent filler. After irradiation, cells were cultured until the visible colonies formed about 10–14 days later. Then, cell clones were fixed with 4% paraformaldehyde (Vicmed, China) and stained with crystal violet (Beyotime, China). The number of colonies was counted by ImageJ software. Plating efficiency (PE) was calculated by the following formula: (the number of colonies/the number of cells plated) × 100%. Survival fraction (SF) was calculated by the following formula: (PE of experimental group/PE of control group) × 100% (22, 23). The relevant parameters such as α, β, D0, Dq, and sensitization enhancement ratio (SERD0 = D0 of experimental group/D0 of control group) and surviving curves were obtained according to the single-hit multitarget model (SF = 1-(1-e-D/D0)N, Dq = D0 × ln(N)) and linear–quadratic model (SF = e-(aD+bD2) by GraphPad Prism 8.0 software. Each experiment was repeated three times.

Transwell assay

Transwell assay was used to assess the cell invasion and migration ability. The cell density was adjusted to 2.5 × 10^5 cells/ml in serum-free medium, and 200 µl was added to the upper chamber with or without Matrigel. Eight hundred microliters of medium with 20% FBS was added to the lower chamber. Cells on the membrane filters were fixed and stained with crystal violet. The number of invasive cells was photographed using a bright microscope and then calculated. Each experiment was repeated three times.
Western blot

Western blot (WB) was used to evaluate the effect of ITGB5 knockout or overexpression efficiency and irradiation (IR) on the expression of DNA damage proteins or other signal pathway proteins in cancer cells with different ITGB5 expression levels. For evaluating expression efficiency, the adherent cancer cells seeded in six-well plates were directly harvested for WB; for expression detection of other proteins, the adherent cancer cells seeded in six-well plates were irradiated with 6 Gy at a dose rate of 300 cGy/min. At different time points after irradiation, cells were harvested for WB as in a previous study (22). Briefly, membranes were incubated with primary antibodies at 4°C overnight and with secondary antibodies for 1 h at room temperature. Then, membranes were washed three times and then imaged with Chemiluminescence Image System. The band intensity was analyzed by ImageJ software. Each experiment was repeated three times.

Cell-cycle assay

Cell-cycle assay was used to examine the effect of ITGB5 expression on pancreatic cancer cell-cycle distribution. Briefly, cancer cells (ITGB5-KO, ITGB-OE, and control BXPC3 cells) were seeded in 6-cm plates with appropriate density. All cells were irradiated with 6 Gy at dose rate of 300 cGy/min. Twenty-four hours after irradiation, all cells were directly harvested using a cell cycle assay kit (KeyGEN BioTECH, KGA512) according to vendors’ instructions and analyzed by flow cytometry. Each experiment was repeated three times.

Xenograft assay

All experiments in vivo were conducted ethically on the basis of the Jiangsu Council on Animal Care. Four- to 6-week-old male BALB/c nude mice (GemPharmatech, China) were adaptively reared at the SPF level Laboratory Animal Center for 1 week before the experiment began. The distal right or left lower extremities of mice were subcutaneously injected with 5 × 10⁶ BXPC3 or PANC-1 cells suspended in 200 μl medium without FBS. Tumor volumes were measured with a caliper every 2 days and calculated by the following formulation: V = 0.5 × a × b² (a is the larger diameter and b is the smaller diameter). Thirty days after subcutaneous neoplasia, mice were euthanized by overdose of carbon dioxide. Subcutaneous tumors were dissected completely and weighted, which were then processed for further detection of ITGB5 and Ki67 expression by IHC. Tumor growth curves were obtained by GraphPad Prism 8.0 software.

Bioinformatics analyses

The expression level of ITGB5 in different types of tumors was obtained from the GEPIA website (http://gepia.cancer.pku.cn/) (24). Gene expression data of PAAD were downloaded and processed from TCGA-PAAD (https://portal.gdc.cancer.gov/) and GTEx (https://xenabrowser.net/datapages/) databases as in our previous study (25). Simply, a total of 171 normal pancreatic samples (167 from GTEx and four from TCGA) and 178 PAAD samples were used to analyze the ITGB5 expression difference. According to the clinical information downloaded from TCGA-PAAD, the samples with incomplete follow-up information were deleted and, ultimately, 173 PAAD samples were used for survival analysis and clinical correlation analysis. Kaplan–Meier (KM) survival curves were used to evaluate the influence of ITGB5 on overall survival (OS) by the “survminer” package in R (V.4.0.2) software. The cutoff value of ITGB5 expression was its median value. Wilcoxon test was used for clinical correlation analysis of ITGB5 expression in R (V.4.0.2) software.

Statistical analysis

All statistical analyses were conducted by SPSS 25. Data were presented as means ± standard deviation (SD). The statistical significance difference was compared by two-sample t-test or one-way ANOVA. The X² test was done to analyze the association between ITGB5 expression and clinical features of PAAD. Kaplan–Meier (K-M) analysis was used to assess survival curves, and log-rank test was used to compare survival curves among groups. p < 0.05 was considered significant.

Results

ITGB5 overexpression related with worse survival in PAAD patients

Firstly, we analyzed ITGB5 expression in cancers by the GEPIA database (Figure 2A). ITGB5 is upregulated in numerous cancer types including PAAD (Ntumor = 179, Nnormal = 171) compared to normal samples. Then, we analyzed the ITGB5 expression difference between PAAD samples and normal pancreatic samples based on TCGA and GTEx databases; ITGB5 is significantly upregulated in PAAD (Figure 2B). KM survival analysis revealed that ITGB5 overexpression is highly bound up with poor prognosis (Figure 2C). Concerning the clinical correlation (Figure 2D), ITGB5 expression was clearly upregulated in patients with a T3&T4 stage or distant metastases compared to patients with T1&T2 stage or non-distant metastases, which highlighted the invasive and metastatic potential of ITGB5 expression in pancreatic cancer. Lastly, we
examined ITGB5 protein expression in TMA containing 90 PAAD samples and 60 normal pancreatic samples. As shown in Figures 2E, F, consistent with the results from the database analysis, ITGB5 is highly regulated in PAAD samples. We further analyzed the relationship of ITGB5 with prognosis and clinical characteristics in PAAD. Samples with incomplete clinical factors were rejected, and a total of 87 PAAD samples were included in the analysis. Clinical characteristics of 90 PAAD samples are summarized in Table 1, of which 39 samples were 60 years old or younger and 48 samples were 60 years old or older. Fifty-six were men and 31 were women. Concerning pancreatic cancer infiltration, 31 samples were coupled with perineural invasion, 52 samples were coupled with lymph node metastasis, and 50 samples were located in the head of pancreas. Most of the PAAD samples had earlier clinical stages, 27 samples were stage I, 59 samples were stage II, and the rest of the samples were stage IV. ITGB5 expression was related with tumor size, lymph node metastasis, and clinical stage significantly (p < 0.05). Besides this, ITGB5 overexpression in PAAD predicted unsatisfactory prognosis (Figure 2G). In conclusion, ITGB5 is not only highly regulated in PAAD compared to normal pancreas but also related with poor prognosis, which can be a potential prognostic marker in PAAD.

**ITGB5 promotes tumor growth, invasion, and metastasis**

To investigate the role of ITGB5 in PAAD, we established ITGB5 knockout or overexpression pancreatic cancer cell lines. Firstly, we examined the expression of ITGB5 in three pancreatic cancer cell lines (BXPC3, PANC-1, and ASPC1) and one normal pancreatic cell line (HPDE6-C7). As shown in Figure 3A, compared to HPDE6-C7, ITGB5 expression was obviously upregulated in...
BXPC3, PANC-1, and ASPC1. Considering that the expression of ITGB5 was highest in PANC-1 and lowest in BXPC3, we used PANC-1 and BXPC3 to construct stable ITGB5 knockout or overexpression cells (Figures 3B, C). CCK-8 results showed that compared to control cells (Lenticrispr V2 or pCDH), knocking out ITGB5 expression in PANC-1 or BXPC3 (ITGB5-KO-1, ITGB5-KO-2) obviously inhibited cell proliferation; on the contrary, upregulated ITGB5 expression in PANC-1 or BXPC3 (ITGB5-OE) obviously promoted cell proliferation (Figures 4A, B). Colony formation assays reached the same conclusion (Figures 4C-F).

Transwell assay showed that ITGB5 overexpression promoted migration and invasion of PAAD cells, which was oppositely inhibited by the silence of ITGB5 (Figure 5).

ITGB5 knockout inhibits xenograft tumor growth in vivo

Based on results in vitro, we further investigated ITGB5 function in vivo by constructing xenograft tumors. Considering that the knockout efficiency of sgITGB5-1 is superior to sgITGB5-2, we used ITGB5-KO constructed by sgITGB5-1 for experiment in vivo. ITGB5-KO and control cells were subcutaneously injected in the distal right and left lower extremities of one mouse, respectively. As shown in Figures 6A, B, ITGB5 depletion significantly inhibited xenograft tumor growth in both PANC-1 and BXPC3 by recording tumor volume and tumor weight. The expression of proliferating protein Ki67 in xenograft tumors was further detected by IHC, which was consistent with ITGB5 expression (Figure 6C). When ITGB5 was downregulated, Ki67 protein expression was inhibited, which further supported the results of in vitro experiments that ITGB5 depletion inhibited tumor proliferation.

ITGB5 promotes radio-resistance in PAAD

To investigate the influence of ITGB5 on radiation sensitivity, ITGB5-KO, ITGB5-OE, and control cells were irradiated with 0, 2, 4, 6, and 8 Gy. According to colony formation assay and survival curves generated using survival fractions at different radiation doses in Figures 7A-F, ITGB5 depletion inhibited the number of colonies and survival curves became steeper (Figures 7G, H). Sensitization enhancement ratios (SERD0) of ITGB5-KO and ITGB5-OE in PANC-1 cells were 1.404 and 0.862, respectively, which in BXPC3 were 1.341.

| Variable               | n   | High | Low | P-value |
|------------------------|-----|------|-----|---------|
| Age                    |     |      |     |         |
| ≤60                    | 39  | 14   | 25  | 0.583   |
| >60                    | 48  | 20   | 28  |         |
| Gender                 |     |      |     | 0.958   |
| Male                   | 56  | 22   | 34  |         |
| Female                 | 31  | 12   | 19  |         |
| Tumor size             |     |      |     | 0.001   |
| ≤4                     | 45  | 10   | 35  |         |
| >4                     | 42  | 24   | 18  |         |
| Perineural invasion    |     |      |     | 0.075   |
| Negative               | 56  | 18   | 28  |         |
| Positive               | 31  | 16   | 15  |         |
| Lymph node metastasis  |     |      |     | 0.041   |
| Negative               | 35  | 6    | 29  |         |
| Positive               | 52  | 28   | 24  |         |
| TNM stage              |     |      |     | 0.005   |
| I                      | 27  | 4    | 23  |         |
| II                     | 59  | 29   | 30  |         |
| III                    | 0   | 0    | 0   |         |
| IV                     | 1   | 1    | 0   |         |
| Tumor location         |     |      |     | 0.810   |
| Head                   | 50  | 19   | 31  |         |
| Non-head               | 37  | 15   | 22  |         |

TABLE 1 The relationship between ITGB5 expression and clinical characteristics in PAAD.
and 0.864 (Table 2). ITGB5 overexpression in pancreatic cancer cells promoted radio-resistance.

We then investigated the possible mechanism by which ITGB5 induces enhanced radio-resistance in pancreatic cancer cells. Firstly, we tested whether ITGB5 overexpression induced more DNA double-strand breaks (DSBs). γ-H2AX, formed at DSBs damage sites, is used as a marker of DNA DSBs (26). WB was further used to detect the γ-H2AX protein expression of ITGB5-KO, ITGB5-OE, and control BXPC3 cells at different time points (0, 2, 4, 6, 8, 24 h) after irradiation. As shown in the results in Figures 8A, B, γ-H2AX protein expression increased 2 h after irradiation in the control group and basically dropped to normal levels after 6–8 h of irradiation. However, in the group of ITGB5-KO BXPC3 cells, γ-H2AX expression increased obviously and was still at a high expression level 24 h after irradiation; on the contrary, in the group of ITGB5-OE cells, γ-H2AX expression was not significantly different from the control group.
H2AX expression was significantly lower than that in the control group. A semiquantitative statistical analysis of the gray level of WB strips showed that 0, 2, 4, 6, 8, and 24 h after irradiation, the expression level of γ-H2AX in ITGB5-KO cells was significantly higher than that in the control group, and the difference was statistically significant. On the contrary, the expression level of γ-H2AX in ITGB5-OE cells was significantly lower than that in the control group.

Secondly, we examined DNA damage repair protein expression (Figure 8C). DNA-PK, ATM (ataxia telangiectasia mutated), and ATR (ataxia telangiectasia and Rad3 related) belong to the phosphatidylinositol 3-kinase-related kinase family (PI3K). DNA-PK and ATM were mainly activated by DSBs, while ATR was mainly activated by single-strand breaks (SSBs). Here, we focused on the effect of ITGB5 on the expression changes of DNA-PK and ATM targeting at DSB
The results showed that Rad51, DNA-PKcs, and KU70/80 protein expression levels were significantly increased in the ITGB5-OE BXPC3 cells and decreased in ITGB5-KO BXPC3 cells compared with control cells (p < 0.05). After irradiation, the expression differences of Rad51, DNA-PKcs, and KU70/80 protein between ITGB5-OE or ITGB5-KO BXPC3 cells and control cells were more obvious (p < 0.01). Another ATM-CHEK2 signaling pathway, ATM, CHEK2, and phospho-CHEK2 (pCHEK2) were highly upregulated in the group of ITGB5-OE. Abnormally increased ITGB5 promoted DNA damage repair by activating DNA-PK and ATM, which then enhanced radio-resistance.

The activation of DNA damage repair proteins may induce cell-cycle arrest. We further examined cell-cycle distribution after irradiation. As shown in Figure 9, in group ITGB5-OE, the proportion of G2/M phase cells was significantly increased and, adversely, the proportion of G2/M phase cells was significantly decreased in group ITGB5-KO.

Lastly, we examined protein expression related with the MEK/ERK signaling pathway (Figure 10). MEK and ERK protein expression showed no significance between ITGB5-KO or ITGB5-OE BXPC3 cells and control cells both before and after irradiation (p > 0.05). However, compared with the control cells, the protein expression levels of p-MEK and p-ERK were
increased in the ITGB5-OE BXPC3 cells and significantly decreased in the ITGB5-KO BXPC3 cells, and the differences were more significant after irradiation (p < 0.05). Besides, in the ITGB5-OE group, PAX6 and STAT1 expression downstream of the MEK/ERK signaling pathway was also significantly increased before and after irradiation. These results suggested that ITGB5 promoted DNA damage repair by activating the MEK/ERK pathway and then enhanced radio-resistance.

Discussion

Integrin, as a member of the family of cell adhesion molecules, is a bridge for intercell or cell–ECM interactions and is strongly linked to the occurrence and evolvement of multiple tumor types. Focusing on the recent findings, the important roles and related mechanisms of integrin in glioma (27–30), melanoma (31), colorectal cancer (32), and breast cancer (33) have been reported. For instance, integrin αvβ3 acts as a cancer stem cell driver factor that regulates the growth and resistance of melanoma (34, 35). The α2β1 integrin along with α3β1, α6β1, and αvβ1 integrins inhibited apoptosis of small cell lung cancer cells induced by chemotherapy and radiation (36). Integrin α2β1 has also been reported to promote tumor cell migration through epithelial-stromal transformation (EMT), leading to the dissemination process of cancers (37). Integrin-mediated cell interactions with ECM fundamentally enhanced cancer cell resistance to treatment.
The study of drug-targeted integrins is of great significance for the clinical treatment of tumors, which has become a promising target for cancer treatment.

Many recent studies have reported the potential role and mechanisms of ITGB5 in tumor progression. ITGB5 mediated TGF-induced EMT in breast cancer cells (6, 38). ITGB5 promoted the occurrence of hepatocellular carcinoma by interacting with the β-catenin protein (8). Furthermore, ITGB5 has been found to be associated with immunomodulation and angiogenesis in the glioblastoma microenvironment and is required

---

**FIGURE 7**

The effect of ITGB5 expression on radiation sensitization in pancreatic cancer cells. (A, C) The colony formation of PANC-1 (A) and BXPC3 (C) cells irradiated with different doses; (B, E) Plating efficiency (PE) of PANC-1 (B) and BXPC3 (E) cells; (C, F) Survival fraction (SF) of PANC-1 (C) and BXPC3 (F) cells; (G-H) Survival fraction curves of PANC-1 (G) and BXPC3 (H) cells according to Linear-quadratic model and Single-hit multitarget model. Values were presented as mean ± SD (n=3).
for the formation of endothelial cells into tubes (9). However, the function of ITGB5 in pancreatic cancer and its effect on radiosensitivity remain to be reported.

Our analysis of ITGB5 expression in authoritative databases and clinical samples in TMA both supported that ITGB5 is significantly upregulated in PAAD, which led to a lower probability of OS. The main causes of poor prognosis in patients with pancreatic cancer include tumor cell proliferation and metastasis. In our study, the forced expression of ITGB5 not only apparently potentiated the proliferation, migration, and invasion of pancreatic cancer cells in vitro but also facilitated the growth of implanted pancreatic tumors in vivo.

At present, RT is one of the main cancer treatment methods, and varying degrees of radio-resistance due to ionized radiation tolerance make the radiotherapy effect unsatisfactory. Consequently, it is a strategic therapeutic option to improve radiosensitivity. In our study, colony formation assay manifested that ITGB5 silencing weakened the vitality of pancreatic cancer cells after irradiation, suggesting that ITGB5 overexpression enhanced innate radiation resistance in PAAD. The primary effect of radiation on cells is to induce DSBs and trigger DDR (39), and radiation can induce large amounts of γ-H2AX, which can act as an early marker of post-radiation DSBs (40–43). We examined the expression of γ-H2AX protein at different time points after irradiation under different ITGB5 expression conditions in BXPC3 cells. We found that in ITGB5-KO BXPC3 cells, the expression level of γ-H2AX was significantly increased and the γ-H2AX peak duration was prolonged. It was also confirmed that ITGB5 knockout delayed radiation-induced DSB repair and thus improved radiosensitivity.

Subsequently, we attempted to further validate the potential molecular mechanism of ITGB5 in decreasing radiosensitivity. Irradiation can induce a series of DDRs; cell-cycle arrest and DNA damage repair are the two main forms of DDRs that protect cancer cells from irradiation (44). Moreover, in mammals, non-homologous end joining (NHEJ) and homologous recombination (HR) are two major DDRs (45). Three kinases in the PI3K family play a leading role in DDR: DNA-PK, ATM, and ATR (44). DNA-PK and ATM mainly responded to DSBs, while ATR mainly responded to SSBs (46, 47). In addition, DNA-PK mainly participates in NHEJ and ATM mainly participates in HR (46). We hypothesized that targeting ITGB5 could affect pancreatic cancer radiosensitivity through the DNA damage repair pathway. Moreover, in our data, high expression of ITGB5 not only induced G2/M phase cell arrest but also effectively activated DNA-PK and ATM-

---

### TABLE 2A Parameters of survival curves in PANC-1 and BXPC3 cells.

| Cell line | Groups   | D0 (Gy) | N  | Dq (Gy) | SF2(%) | SERD0 |
|-----------|----------|---------|----|---------|--------|-------|
| PANC-1    | Control  | 1.855   | 2.379 | 1.608   | 63.636 |       |
|           | ITGB5-OE | 2.152   | 3.395 | 2.630   | 83.838 | 0.862 |
|           | ITGB5-KO | 1.321   | 2.467 | 1.193   | 45.936 | 1.404 |
| BXPC3     | Control  | 2.178   | 1.602 | 1.026   | 55.642 |       |
|           | ITGB5-OE | 2.522   | 3.558 | 3.201   | 88.366 | 0.864 |
|           | ITGB5-KO | 1.624   | 1.617 | 0.781   | 42.831 | 1.341 |

### TABLE 2B Survival fractions (%) of PANC-1 and BXPC3 cells in different groups irradiated with different doses.

| Group | Dose(Gy) | Control | ITGB5-KO | ITGB5-OE |
|-------|----------|---------|----------|----------|
|       | Average  | SD      | RSD      | Average  | SD      | RSD      | Average  | SD      | RSD      |
| PANC-1| 0        | 100.066 | 4.576    | 4.548    | 100.457 | 11.072   | 11.022   | 100.000  | 7.873   | 7.873    |
|       | 2        | 63.636  | 5.455    | 8.571    | 45.936  | 2.795    | 6.085    | 83.838   | 3.813   | 4.548    |
|       | 4        | 23.106  | 3.991    | 17.272   | 10.845  | 2.616    | 24.119   | 40.720   | 3.414   | 8.385    |
|       | 6        | 10.303  | 2.922    | 28.364   | 3.653   | 0.791    | 21.651   | 20.202   | 2.314   | 11.456   |
|       | 8        | 6.061   | 1.050    | 17.321   | 1.522   | 0.527    | 34.641   | 10.943   | 1.031   | 9.608    |
| BXPC3 | 0        | 100.086 | 1.301    | 1.299    | 100.000 | 2.903    | 2.903    | 100.000  | 2.508   | 2.508    |
|       | 2        | 55.642  | 2.652    | 4.766    | 42.831  | 7.074    | 16.516   | 88.366   | 0.804   | 0.910    |
|       | 4        | 24.649  | 2.195    | 8.906    | 13.152  | 0.727    | 5.527    | 54.200   | 1.126   | 2.078    |
|       | 6        | 10.140  | 0.241    | 2.375    | 4.214   | 1.177    | 27.941   | 33.423   | 0.225   | 0.674    |
|       | 8        | 3.192   | 0.359    | 11.235   | 1.552   | 0.284    | 18.330   | 10.374   | 1.229   | 11.850   |
related DNA damage repair signaling pathways. These results suggested that ITGB5 increased the radiation resistance of pancreatic cancer cells by promoting DSB damage repair.

Previous studies demonstrated that the abnormal activation of Ras/Raf/MEK/ERK cascade mediates resistance to irradiation in cancer cells (48). Huang et al. (49) reported that the ERK pathway can increase radiation resistance of glioma. Another study found that sorafenib increased radiosensitivity of lung cancer cells by inhibiting ERK phosphatization (50). Our study demonstrated that the silencing of ITGB5 leads to downregulation of phosphorylated MEK/ERK, which enhanced DNA damage and radiosensitivity, which is in line with previous studies. Besides, activation of the ERK pathway can further promote DSB-induced ATM activation (51, 52).

FIGURE 8
Effect of ITGB5 expression on DNA damage proteins expression levels in BXPC3 cells. (A, B) The effect of ITGB5 overexpression (A) and ITGB5 knockout (B) on γ-H2AX expression at different time points after irradiation in BXPC3 cells. (C) the effects of ITGB5 overexpression and knockout on DNA injury repair protein expression in BXPC3 cells before and after irradiation. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
FIGURE 9
Effect of ITGB5 expression on the cell-cycle distribution in BXPC3 cells irradiated by 6 Gy. (A) Results of cell cycle flow cytometry in BXPC3 cells; (B) The statistical analysis results of cell cycle in BXPC3 cells. ****p < 0.0001.

FIGURE 10
Effect of ITGB5 expression on MEK/ERK signaling protein expression levels in BXPC3 cells before and after irradiation. *p < 0.05, **p < 0.01, ****p < 0.0001. "ns", Not Statistically.
On the whole, our experiment results unveil ITGB5 as a novel anticancer target and a potential prognostic marker in PAAD.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. The animal study was reviewed and approved by Xuzhou Medical University.

Author contributions

XW performed the study design, wrote and edited the manuscript. SC performed the experimental research. XC performed data analysis and conducted part experiments in revised manuscript. HQ contributed to the writing and editing of the manuscript. WW, NZ, WL, TW contributed to data analysis. XD and LZ performed the study design, paper guidance, and financial support. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by National Natural Science Foundation of China (No. 81972845), and Specialist Team in Clinical Medicine of Xuzhou (No.2019TD003)

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistic. CA Cancer J Clin (2019) 69 (1):7–34. doi:10.3332/caac.215551
2. Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, et al. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun (2021) 12(1):4626. doi:10.1038/s41467-021-24798-y
3. Rahb I, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of cancer. CA Cancer J Clin (2017) 67(1):35. doi:10.3322/caac.21551
4. Takada Y, Ye X, Simon S. The integrins. Genome Biol (2007) 8(5):215. doi:10.1186/gb-2007-8-5-215
5. Degroselle JS, Chereda DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 10(1):9–22. doi:10.1038/nrc2748
6. Bianchi-Smiraglia A, Paesante S, Bakin AV. Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the src-FAK and MEK-ERK signaling pathways. Oncogene (2013) 32(25):3049–58. doi:10.1038/onc.2012.320
7. Haas TL, Sciuto MR, Brunetto L, Valvo C, Signore M, Fiori ME, et al. Integrin alpha7 is a functional marker and potential therapeutic target in glioblastoma. Cell Stem Cell (2017) 21(3):35–50 e38. doi:10.1016/j.stem.2017.04.009
8. Lin Z, He R, Luo H, Li C, Ning Z, Wu Y, et al. Integrin-beta5, a miR-185-targeted gene, promotes hepatocellular carcinoma tumorigenesis by regulating beta-catenin stability. J Exp Clin Cancer Res (2018) 37(1):17. doi:10.1186/s13046-018-0691-9
9. Zhang LY, Guo Q, Guan GP, Cheng W, Cheng P, Wu AH. Integrin beta 5 is a prognostic biomarker and potential therapeutic target in glioblastoma. Front Oncol (2019) 9:904. doi:10.3389/fonc.2019.00904
10. Badiyan SN, Molitoris JK, Chuong MD, Regine WF, Kaiser A. “The role of radiation therapy for pancreatic cancer in the adjuvant and neoadjuvant settings. Surg Oncol Clin N Am (2017) 26(3):431–53. doi:10.1016/j.soc.2017.01.012
11. Falta M, Godfrey D, Goodman KA, Hofe S, Dawson LA, Desert D, et al. Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol (2019) 9(5):322–32. doi:10.1016/j.prro.2019.06.016
12. Paramananthan A, Jung EJ, Go SI, Jeong BK, Jung JM, Hong SC, et al. Activated ERK signaling is one of the major hub signals related to the acquisition of radiotherapy-resistant MDA-MB-231 breast cancer cells. Int J Mol Sci (2021) 22(9):4940. doi:10.3390/ijms22094940
13. Mochmann LH, Neumann M, von der Heide EK, Nowak V, Kuhl AA, Ortiz-Tanchez J, et al. ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells. Oncotarget (2014) 5(2):351–62. doi:10.18632/oncotarget.1449
14. Wang S, Xie J, Li J, Liu F, Wu X, Wang Z. Cisplatin suppresses the growth and proliferation of breast and cervical cancer cell lines by inhibiting integrin beta5-mediated glycolysis. Am J Cancer Res (2016) 6(5):1108–17.
doi:10.1002/cncr.28864
15. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 16(1):103–19. doi:10.1517/14728222.2011.65805
16. Fufa TD, Baxter LL, Wedel JC, Gildea DE, Program NCS, Loftus SK, et al. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells. Epigenet Chromatin (2019) 12(1):50. doi:10.1186/s13072-019-0297-2
17. Burotto M, Chiuo V, Lee JM, Kohn EC. The MAPK pathway across different malignancies: A new perspective. Cancer (2014) 120(22):3446–56. doi:10.1002/cncr.28864
Integrin is associated with decreased survival in invasive breast cancer. *Biomol Ther* (Seoul) (2021) 30(3):274–83. doi: 10.4062/biomolther.2021.450

Marampon F, Gravina GL, Di Rocco A, Bonfill P, Di Staso M, Fardella C, et al. MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. *Mol Cancer Ther* (2011) 10(1):159–68. doi:10.1158/1535-7163.MCT-10-0631

Laban K, Montague TG, Gagnon JA, Thyreme SB, Valen E. CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering. *Nucleic Acids Res* (2016) 44(W1):W272–276. doi: 10.1093/nar/gkw398

Liu N, Wu Z, Chen A, Wang Y, Cai D, Zheng J, et al. SNRPB promotes the tumorigenic potential of NSCLC in part by regulating RAB26. *Cell Death Dis* (2019) 10(9):667. doi:10.1038/s41419-019-1929-y

Yao H, Qiu H, Shao Z, Wang G, Wang J, Yao Y, et al. Nanoparticle formulation of small DNA molecules, dbait, improves the sensitivity of hormone-sensitive prostate cancer to radiotherapy. *Nanomedicine* (2016) 12(8):2261–71. doi: 10.1016/j.nano.2016.06.010

Wen X, Qiu H, Shao Z, Liu G, Liu N, Chen A, et al. Pulsed low-dose-rate radiotherapy has an improved therapeutic effect on abdominal and pelvic malignancies. *J Zhejiang Univ Sci B* (2021) 22(9):774–81. doi:10.1631/jzus.B2000793

Tang Z, Li C, Kang B, Gao Q, Li C, Zhang Z. GEPPA: A web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* (2017) 45(W1):W98–W102. doi: 10.1093/nar/gkw398

Wen X, Shao Z, Chen S, Wang W, Wang Y, Jiang J, et al. Construction of a RNA-binding protein-related prognostic model for pancreatic adenocarcinoma based on TCGA and GTEx databases. *Front Genet* (2021) 11:1791. doi: 10.3389/fgene.2020.60350

Olve PL. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. *Methods Cell Biol* (2004) 75:e8420. doi:10.1016/S0091-679X(04)75014-1

Renner G, Januszkowa H, Noedl F, Koening V, Guerin E, Bar S, et al. Integrin alpha5beta1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma. *EMBO Mol Med* (2018) 10(9). doi: 10.15252/emmm.201708420

Fujita M, Yamamoto T, Iyoda T, Fujisawa T, Nagai R, Kudo C, et al. Autocrine production of PDGF stimulated by the tenasin-C-derived peptide NTNIIA2 induces hyper-proliferation in glioblastoma cells. *Int J Mol Sci* (2019) 20(13):3183. doi: 10.3390/ijms20133183

Zhu X, Yao T, Lu W, Ding Y, Tang Y. Blockade of integrin beta3 signals to reverse the stem-like phenotype and drug resistance in melanoma. *Cancer Chemother Pharmacol* (2019) 83(4):615–24. doi: 10.1007/s00228-018-3760-z

Huang L, Li B, Tang T, Guo H, Li W, Huang X, et al. Mitochondrial KEAP1 controls checkpoint of gloma radiosensitivity by regulating ROS-induced ERK activation. *Mol Neurobiol* (2015) 52(1):626–37. doi:10.1007/s12035-014-8881-8

Laban S, Steinmeister L, Glessner L, Grob TJ, Gremman R, Petersen C, et al. Serine/threonine kinase 6 sensitizes head and neck squamous cell carcinoma cells to radiosensitization. *Radiother Oncol* (2013) 109(2):286–92. doi:10.1016/j.radonc.2013.07.003

Wei F, Xie Y, Yao T, Liang D. Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. *Cell Signal* (2010) 22(11):1783–9. doi:10.1016/j.cellsig.2010.07.007

Heo HJ, Oh SJ, Kho YJ, Kim HJ, Kang HJ, Park SH, et al. ATM Mediates interdependent activation of p53 and ERK through formation of a ternary complex with p-p53 and p-ERK in response to DNA damage. *Mol Enzym Biol Rep* (2012) 39(8):8007–14. doi:10.1016/j.spmem.2012.1647-3